CID1633 - Physician's Weekly


Advertisement

CID1633

Sex Differences in Anti-PD-1/Anti-PD-L1 Treatment for NSCLC

For the treatment of non-small cell lung cancer (NSCLC), anti-PD-1/anti-PD-L1 monotherapy is highly effective in men but not in women, even in NSCLC that expresses high PD-L1 levels, explain Fabio Conforti, MD, and Laura Pala,...

Postoperative Nutrition May Affect Early-Stage NSCLC Outcomes

Postoperative changes in nutritional status may be important in early-stage NSCLC outcomes, according to a study published in PLoS One. Although preoperative nutritional status is an important host-related prognostic factor for...

Gene Expression Profile Improves Early-Stage NSCLC Survival

A clinically certified gene expression profile improved survival in a cohort of patients with stage I-IIA NSCLC by identifying those likely to benefit from adjuvant intervention, independent of epidermal growth factor receptor...

Atezolizumab Favorable After Adjuvant Chemotherapy

Atezolizumab after adjuvant chemotherapy offers a promising treatment option for patients with resected early-stage NSCLC, according to a study published in The Lancet. Researchers who evaluated adjuvant atezolizumab versus best...

Patient-Reported Outcomes

This study states that Historically, the prognosis for patients with metastatic non–small-cell lung cancer (NSCLC) has been poor, with 5-year survival of approximately 6%.1 However, the introduction of immune checkpoint...

Immune Checkpoint Inhibitor Therapy

This article has been reviewed so that we could detect how Cancer immunotherapy with immune checkpoint inhibitors (ICIs) has revolutionized the management of a wide variety of malignancies. ICIs, such as monoclonal antibodies...

Loading

Advertisement

For latest news and updates
Email-id is invalid